➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Moodys
Merck
Harvard Business School
Boehringer Ingelheim

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IRBESARTAN AND HYDROCHLOROTHIAZIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Irbesartan And Hydrochlorothiazide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00095394 ↗ Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension Completed Sanofi Phase 3 2004-09-01 The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
NCT00095394 ↗ Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension Completed Bristol-Myers Squibb Phase 3 2004-09-01 The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
NCT00095550 ↗ Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension Completed Sanofi Phase 3 2004-10-01 The purpose of this clinical research is to learn if moderate hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
NCT00095550 ↗ Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension Completed Bristol-Myers Squibb Phase 3 2004-10-01 The purpose of this clinical research is to learn if moderate hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
NCT00110422 ↗ Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome Completed Sanofi Phase 4 2005-11-01 The purpose of this clinical research study is to learn if irbesartan is superior to hydrochlorothiazide relative to effects on insulin sensitivity and glucose metabolism in hypertensive patients with metabolic syndrome.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Irbesartan And Hydrochlorothiazide

Condition Name

Condition Name for Irbesartan And Hydrochlorothiazide
Intervention Trials
Hypertension 13
Healthy 1
Type 2 Diabetes 1
Microalbuminuria 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Irbesartan And Hydrochlorothiazide
Intervention Trials
Hypertension 9
Albuminuria 1
Syndrome 1
Metabolic Syndrome X 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Irbesartan And Hydrochlorothiazide

Trials by Country

Trials by Country for Irbesartan And Hydrochlorothiazide
Location Trials
United States 71
Canada 18
Germany 6
Taiwan 4
France 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Irbesartan And Hydrochlorothiazide
Location Trials
Texas 4
Florida 2
Pennsylvania 2
South Carolina 2
Alabama 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Irbesartan And Hydrochlorothiazide

Clinical Trial Phase

Clinical Trial Phase for Irbesartan And Hydrochlorothiazide
Clinical Trial Phase Trials
Phase 4 9
Phase 3 3
N/A 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Irbesartan And Hydrochlorothiazide
Clinical Trial Phase Trials
Completed 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Irbesartan And Hydrochlorothiazide

Sponsor Name

Sponsor Name for Irbesartan And Hydrochlorothiazide
Sponsor Trials
Sanofi 10
Bristol-Myers Squibb 4
Roxane Laboratories 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Irbesartan And Hydrochlorothiazide
Sponsor Trials
Industry 16
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Dow
Express Scripts
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.